Regina Marek

Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The firm's product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company was founded by Joseph H. Garder on November 16, 2007 and is headquartered in Cincinnati, OH.

Milacron Holdings Corp. engages in the manufacture and distribution of plastic technology products. It operates through the following business segments: Advanced Plastic Processing Technologies (APPT), Melt Delivery and Control Systems (MDCS), Fluid Technologies, and Corporate. The APPT segment involves in the design, manufacture, and sale of plastic processing equipment and systems, which include injection molding, blow molding, extrusion, and auxiliary systems along with the related parts and service. The Fluid Technologies segment produces metalworking processes such as cutting, grinding, stamping, and forming and high speed machining. The company was founded in 1860 and is headquartered in Cincinnati, OH.

Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY.